BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Dr. Lal Path Labs strengthens autoimmune diagnosis with Indiaâ??s first comprehensive complement lab

26 November 2025 | News

Offering several tests made available in the country for the very first time

Dr. Lal PathLabs (DLPL), one of India's leading diagnostic networks, has announced the launch of India's first dedicated Complement Testing Laboratory, strengthening its position as India's leading hub for autoimmune diagnostics.

This advanced facility brings globally benchmarked complement assays to Indian patients, several for the first time in the country, helping doctors diagnose autoimmune, kidney, and recurrent infection related conditions faster, more accurately, and at earlier stages.

Autoimmune and inflammatory diseases are increasingly being recognized across India, with more patients seeking care for conditions that often begin with vague, overlapping symptoms. Many individuals experience fever, joint pain, swelling, fatigue, or kidney-related issues and may consult multiple doctors before receiving a clear diagnosis.

These delays occur because autoimmune diseases can progress silently, affecting vital organs long before symptoms become obvious. Complement testing helps uncover the underlying immune disturbance and provide clarity on why these symptoms occur and enabling earlier, more accurate diagnosis and treatment.

The complement system is a group of blood proteins that help fight infections, clear damaged cells, and protect vital organs. When this system is weak, the body, especially children, becomes prone to repeated or severe infections. When it becomes overactive, it can mistakenly attack healthy tissues, contributing to conditions such as lupus, certain kidney diseases like C3 glomerulopathy and atypical haemolytic uremic syndrome (HUS), vasculitis, rheumatoid arthritis, transplant rejection, and even sepsis.

The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards.